Close menu

August 21st, 2023 | 07:15 CEST

Meyer Burger, Saturn Oil + Gas, CureVac - Incisive events

  • Mining
  • Oil
  • Biotechnology
  • Technology
Photo credits:

The past week in the stock market, due to the earnings season for the year's first half, brought surprises on both sides. Some companies were able to shine despite uncertainties on the economic and geopolitical side and face a golden future due to a significant undervaluation. Speaking of the future: Due to weaker market conditions, one company after another is leaving the old contingent to take advantage of better conditions overseas.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: MEYER BUR.TECH.NAM.SF-_05 | CH0108503795 , Saturn Oil + Gas Inc. | CA80412L8832 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:

    Meyer Burger - Goodbye Germany

    Since 2006, VOX has been following Germans who want to try their luck abroad in the docu-soap "Goodbye Deutschland! Die Auswanderer". The show focuses on people who long for sun and sea or see no career prospects in "good old Germany." Due to the lack of future prospects, however, even large companies are now joining the trend, especially since the exploding energy costs. Meyer Burger, the only solar cell manufacturer in Europe, has announced its decision. The Swiss company is shifting its strategic focus from Europe to the US, at least for the time being.

    This results from the unfavorable market conditions in Europe, characterized by unprotected competition with producers selling far below their production costs. Meyer Burger emphasized that more favorable production conditions exist in the US, while in Germany, they are under pressure from Chinese suppliers flooding the market with low-cost modules. In July, Meyer Burger announced that it would pause its planned expansion in Saxony-Anhalt and instead invest in Colorado, US.

    Between the two, Swiss solar company Meyer Burger further consolidated its position in the first half of 2023, releasing sales figures showing a 70.8% YOY increase. However, price pressure from Chinese suppliers flooding the market with cheap modules made things difficult. Nevertheless, the Company managed to maintain stable sales prices in the first quarter - special effects due to impairments and credit notes depressed earnings by CHF 13.0 million. An increase in personnel and operating costs, particularly due to the start-up of new production lines, resulted in an operating loss of CHF 43.3 million. The net loss amounted to CHF 64.8 million, whereas liquidity stood at CHF 370 million and the equity ratio at 45.9%.

    With the publication of the figures, the Meyer Burger share continued its months-long slide to CHF 0.406. Since mid-July, when a sales warning was announced, the stock has lost around 38%.

    Saturn Oil + Gas - Records upon records

    In complete contrast to the Swiss solar cell producer, the Canadian producer of light oil, natural gas and natural gas liquids, Saturn Oil & Gas, was able to report record results due to successfully completed acquisitions over the past two years. In this regard, the end of the second quarter marks a significant milestone following the complete integration of Ridgeback Resources.

    YOY quarterly production increased to 25,988 barrels of oil equivalent per day (boe/d), compared to 7,324 boe/d in the second quarter of 2022, while resulting quarterly revenue also reached record highs of CAD 176.0 million, compared to CAD 82.2 million in the year-ago quarter.

    The Company, led by CEO John Jeffrey, achieved another record high with an adjusted cash flow of CAD 67.0 million, or CAD 0.48 per share. The comparable figure for the previous year of CAD 14.5 million was thus pulverized. At the same time, net operating income, net of derivatives, is a high CAD 41.87 per barrel of oil equivalent, while the benchmark WTI oil price for the period was USD 73.75.

    Saturn's financial strength is also reflected in its consistent debt reduction. Repayments of a substantial CAD 51.5 million were made during the quarter, underscoring the Company's determination to maintain a strong balance sheet and proactively reduce financial obligations.

    Canaccord Genuity analysts continue to see Saturn Oil as a speculative buy candidate following the quarterly results, which met their set forecasts and reiterated their price target of CAD 6.50. The current share price represents an upside potential of around 146%.

    CureVac - Loss widened

    Compared to its peer group, the vaccine manufacturer CureVac has clearly outperformed since the beginning of the year with a price increase of around 53% but bounced off its 200-day line at USD 10.14 due to weak half-year figures. The share is currently trading at USD 8.91. The chart picture would brighten if the downward trend at USD 9.96 formed at the end of June were overcome. In the south, however, the upward trend established since the beginning of the year at USD 7.61 is of importance.

    The financial results for the first half of 2023 showed a mixed picture. While the Company's cash position increased from EUR 495.8 million at the end of 2022 to EUR 537.9 million in June 2023, mainly thanks to a capital increase in February, CureVac saw a marked decline in sales. Compared to the same period last year, revenues fell 62.2% in the second quarter and as much as 67.0% for the first half of 2022, mainly due to declining revenues from collaborations with GSK.

    The operating loss, on the other hand, increased significantly from minus EUR 75.6 million to minus EUR 132.2 million compared to the same period last year, also due to increased research and development expenses in the areas of infectious diseases and oncology. In addition, patent disputes, in particular a lawsuit against Pfizer/BioNTech in Germany, had a negative impact.

    Saturn Oil & Gas reported record second-quarter figures. In contrast, solar cell manufacturer Meyer Burger and biotech company CureVac both struggled with rising losses.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by Nico Popp on September 28th, 2023 | 09:05 CEST

    Germany - Car Country? The exodus begins: Mercedes-Benz, Volkswagen, First Phosphate

    • Mining
    • phosphate
    • Electromobility
    • Energy

    Cars still play a significant role in Germany. Many households have two vehicles, some even more. However, sales of new cars have weakened recently - the question of whether to buy a combustion engine or an electric vehicle, along with inflation, have deterred many buyers. German brand manufacturers are now being attracted to the US. There, they are enticed by subsidies and an intact market. Find out what the latest plans of Mercedes-Benz, Volkswagen, and others entail and which relatively unknown company could benefit.


    Commented by André Will-Laudien on September 28th, 2023 | 08:05 CEST

    Attention: Extended correction - Buy the right stocks now! Bayer, Viva Gold, TUI, and BASF are on the list!

    • Mining
    • Gold
    • Pharma
    • chemicals
    • travel

    Higher inflation and rising interest rates - this connection should be clear to investors. The interest rate level in Germany has moved from negative territory to 2.77% in the 10-year range, but stocks continued to rise cheerfully. The party led to all-time highs of 16,528 points in July, but the fundamental situation of the companies deteriorated in parallel. Only after repeated warnings from the US Federal Reserve did the explosive NASDAQ also enter a correction. And it continues. Yesterday, the CEO of US investment bank JPMorgan, Dimon, warned that the world may not be prepared for 7% capital market interest rates. He and Dr. Jens Erhardt, the CEO of the asset management company DJE, warn of stronger setbacks on the stock markets. Some stocks have already undergone a strong correction. Here is a brief overview.